Daewoong Pharmaceutical Co Ltd
069620
Company Profile
Business description
Daewoong Pharmaceutical Co Ltd develops, manufactures and sells prescription drug products. The company's product portfolio comprises products such as Moxicle, Plunazol Cap, Bearcef tab, Newdizime etc. It develops and promotes brands such as Ursa, Nabota, Luphere, Easyef, Cretropin. The company has manufacturing facilities at Hyangnam and Sungnam.
Contact
12, Bongeunsa-ro 114-gil
Daewoong Pharmaceutical Building
Gangnam-gu
Seoul
KORT: +82 25508800
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
1,777
Stocks News & Analysis
stocks
ASX property share lifts guidance despite sector headwinds
Aussie property manager lifts earnings expectations despite interest rate uncertainty.
stocks
Why stocks sometimes fall for no obvious reason
How the private markets impact all equity investors.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,904.70 | 26.20 | 0.30% |
| CAC 40 | 8,173.11 | 85.15 | -1.03% |
| DAX 40 | 25,184.89 | 204.21 | -0.80% |
| Dow JONES (US) | 50,461.68 | 118.02 | -0.23% |
| FTSE 100 | 10,491.39 | 25.13 | 0.24% |
| HKSE | 25,381.51 | 217.94 | -0.85% |
| NASDAQ | 26,656.18 | 312.21 | 1.19% |
| Nikkei 225 | 65,633.61 | 637.52 | 0.98% |
| NZX 50 Index | 13,207.71 | 137.97 | 1.06% |
| S&P 500 | 7,519.12 | 45.65 | 0.61% |
| S&P/ASX 200 | 8,674.80 | 22.60 | 0.26% |
| SSE Composite Index | 4,099.23 | 46.14 | -1.11% |